AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where AUPH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AUPH's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on January 27, 2025. You may want to consider a long position or call options on AUPH as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on January 27, 2025. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
AUPH moved below its 50-day moving average on January 06, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AUPH crossed bearishly below the 50-day moving average on January 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AUPH entered a downward trend on January 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.952) is normal, around the industry mean (15.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.784). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.848). AUPH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.252) is also within normal values, averaging (276.027).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics
Industry Biotechnology
A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.
Ticker / NAME | Correlation To AUPH | 1D Price Change % | ||
---|---|---|---|---|
AUPH | 100% | -1.72% | ||
JSPR - AUPH | 44% Loosely correlated | +15.92% | ||
VCYT - AUPH | 39% Loosely correlated | +3.83% | ||
GOSS - AUPH | 37% Loosely correlated | +4.91% | ||
ADMA - AUPH | 32% Poorly correlated | -1.71% | ||
SCPH - AUPH | 31% Poorly correlated | +4.86% | ||
More |